Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli

被引:35
作者
Durham, L. K. [1 ]
Ge, M. [1 ]
Cuccia, A. J. [1 ]
Quinn, J. P. [1 ]
机构
[1] Pfizer, New London, CT 06320 USA
关键词
Fluoroquinolone; Resistance Rate; Standard Unit; Fluoroquinolone Resistance; Hospital Isolate;
D O I
10.1007/s10096-009-0862-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
While the development of resistance to a new antibiotic is expected, the time course and degree of resistance that will develop are uncertain. Some best projections of the future extent of resistance can be highly impactful for activities, such as antimicrobial development, that require significant lead time. We focus on the surge among hospital isolates in fluoroquinolone-resistant Escherichia coli and use data on resistance and consumption to explore and quantify trends in increasing resistance and their relationship to antibiotic use from 2001 to 2007. A mixed-effects logistic regression model produced a good fit to the observed resistance rates during this period in the United States and Europe. The model contained significant effects of time, consumption, and country on developing fluoroquinolone resistance in E. coli. There was a larger projected increase in resistance for high fluoroquinolone-consuming countries projected to 2013: 45% (95% confidence interval [CI]: 38%, 53%) for high consumers vs. 33% (95% CI: 25%, 41%) for low consumers. The model was also used to obtain regional projections of resistance that can be used by local prescribers. In order to better understand and predict trends in antimicrobial resistance, it is vital to implement and expand current surveillance systems.
引用
收藏
页码:353 / 356
页数:4
相关论文
共 8 条
[1]   The pandemic of antibiotic resistance [J].
Anderson, RM .
NATURE MEDICINE, 1999, 5 (02) :147-149
[2]  
Bates Douglas., 2008, LINEAR MIXED MODEL I
[3]  
*EUR ANT RES SURV, 2007, EARSS ANN REP 2007
[4]   Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance [J].
Jones, Ronald N. ;
Kirby, Jeffrey T. ;
Rhomberg, Paul R. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 61 (02) :203-213
[5]   The rise and fall of antimicrobial resistance [J].
Lipsitch, M .
TRENDS IN MICROBIOLOGY, 2001, 9 (09) :438-444
[6]  
NEU HC, 1987, AM J MED, V82, P395
[7]   Trends in development and approval times for new therapeutics in the United States [J].
Reichert, JM .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :695-702
[8]  
SAS Institute Inc, 2003, SAS ONLINEDOC 9 1 2